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Testing new interventions to reduce the MTCT risk in
resource-limited settings with an RCT faces various chal-
lenges. Pregnant and lactating women with an advanced
HIV disease require long-term antiretroviral treatment
(ART) for their own health, which reduces substantially
MTCT risk. For those not eligible for ART, PMTCT inter-
ventions from the 3rd trimester with combination ARVs
and modified infant feeding practices greatly reduces risk.
At present such MTCT-prevention interventions remain
too complex to be considered as standard of care in
resource-limited settings. However, in an RCT those inter-
ventions must be provided to all participants in the con-
trol arm. The residual MTCT risk is therefore low
(considerably less than 10%), and the sample size needed
to demonstrate the benefit of any new intervention is now
much larger (at least 1000 mother-infant pairs) than
when pioneer MTCT-prevention interventions were devel-
oped.
HIV prevention research, and MTCT in particular, is a rap-
idly evolving field. However, conducting an RCT requires
time: protocols often have to be adapted to reflect interim
findings from other studies, thus delaying the conduct of
an RCT and making interpretation of results more com-
plex. When finally available RCT results may be less rele-
vant, as practice evolves, frequently based on results from
observational studies.
The cost of such RCTs is high due to: the large sample size
needed; the need to ensure HIV care during and after the
trial; the large multidisciplinary team needed to ensure
care of the participants, analyse specimens and data, and
ensure adequate documentation for Good Clinical Prac-
tice standards; the need for a multi-site study to achieve
the sample size as rapidly as possible, thus increasing staff
and infrastructure. The expected benefit/cost ratio of con-
ducting an RCT for testing MTCT-prevention interven-
tions may therefore become ethically questionable.
Securing funding for such trials becomes more difficult as
most funds are directed at implementing and expanding
PMTCT interventions already proven effective and
expanding access to HIV care. Therefore, future RCTs on
MTCT prevention in resource-limited settings may be
hard to implement. The same may apply to other HIV-pre-
vention research.
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